Salud financiera de hoja de balance de Harvard Bioscience

Salud financiera controles de criterios 5/6

Harvard Bioscience tiene un patrimonio de los accionistas total de $65.3M y una deuda total de $38.1M, lo que sitúa su ratio deuda-patrimonio en 58.3%. Sus activos y pasivos totales son $131.2M y $65.9M respectivamente.

Información clave

58.3%

Ratio deuda-patrimonio

US$38.08m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$4.57m
Patrimonio	US$65.32m
Total pasivo	US$65.92m
Activos totales	US$131.24m

Actualizaciones recientes sobre salud financiera

These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Apr 19

Recent updates

Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?

Nov 07

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Aug 07

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Jul 15

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Dec 22

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Sep 23

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 10

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Apr 26

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Apr 11

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Aug 04

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Jun 08

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Mar 15

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Feb 16

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Nov 04

Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

Oct 01

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

May 04

These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Apr 19

Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Apr 04

Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

Mar 20

What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Mar 07

Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

Feb 17

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Feb 02

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($46.8M) de HBIO superan a sus pasivos a corto plazo ($22.8M).

Pasivo a largo plazo: Los activos a corto plazo de HBIO ($46.8M) superan a sus pasivos a largo plazo ($43.2M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de HBIO (51.3%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de HBIO ha pasado de 71.3% a 58.3% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Aunque no es rentable HBIO tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.

Pronóstico de cash runway: HBIO no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 4.1% al año.

Descubre empresas con salud financiera

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2024/12/23 08:13
Precio de las acciones al final del día	2024/12/20 00:00
Beneficios	2024/09/30
Ingresos anuales	2023/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .

Fuentes analistas

Harvard Bioscience, Inc. está cubierta por 7 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Raymond Myers	Benchmark Company
Bruce Jackson	Benchmark Company
Paul Knight	Janney Montgomery Scott LLC

Salud financiera de hoja de balance de Harvard Bioscience

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Recent updates

Harvard Bioscience, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024

Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?

Harvard Bioscience, Inc. to Showcase Innovative Technologies at Society for Neuroscience Annual Meeting 2024

Harvard Bioscience, Inc. to Showcase Latest Solutions for Preclinical and Organoid Applications At Safety Pharmacology Society Annual Meeting

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2024

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Harvard Bioscience, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Harvard Bioscience, Inc. Provides Earnings Guidance for the Full Year 2024

Harvard Bioscience, Inc. to Report Q1, 2024 Results on May 07, 2024

Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth

Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology Meeting

Harvard Bioscience, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023

Harvard Bioscience, Inc. to Showcase Latest Innovations in Preclinical and Organoid Research At Society for Neuroscience Conference

Harvard Bioscience, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

President recently bought US$110k worth of stock

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New minor risk - Shareholder dilution

Harvard Bioscience, Inc. Provides Earnings Guidance for Full Year 2023

Now 22% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Harvard Bioscience, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Now 20% undervalued

Harvard Bioscience, Inc. Appoints Jennifer Cote as Chief Financial Officer

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

President recently bought US$105k worth of stock

Forecast breakeven date moved forward to 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Harvard Bioscience, Inc. Announces CFO Changes

President recently bought US$75k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: US$0.082 loss per share (vs US$0.004 loss in 3Q 2021)

Harvard Bioscience, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insufficient new directors

Insufficient new directors

Lead Independent Director recently bought US$83k worth of stock

President recently bought US$128k worth of stock

Forecast breakeven date pushed back to 2023

Price target decreased to US$8.50

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Harvard Bioscience, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Harvard Bioscience, Inc.(NasdaqGM:HBIO) dropped from Russell 2000 Dynamic Index

President recently bought US$111k worth of stock

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

President recently bought US$147k worth of stock

Forecast breakeven date pushed back to 2023

First quarter 2022 earnings released: US$0.17 loss per share (vs US$0.017 loss in 1Q 2021)

Harvard Bioscience, Inc. Introduces Smartstudy™ First of Kind, Next Generation Inhalation System Capability Improves Precision and Drives Growth

Harvard Bioscience, Inc. to Report Q1, 2022 Results on May 04, 2022

Harvard Bioscience, Inc., Annual General Meeting, May 17, 2022

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Full year 2021 earnings: EPS misses analyst expectations

Harvard Bioscience, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Harvard Bioscience, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2022

Third quarter 2021 earnings released: US$0.004 loss per share (vs US$0.028 loss in 3Q 2020)

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?